CTRI/2018/09/015815已完成未知
A multi-center, open-label, balanced, randomized, two-treatment, two-period, two-sequence, two-way crossover, steady-state bioequivalence study of Felbamate Tablets 600mg of Lannett Company Inc., USA with FELBATOL® (Felbamate) Tablets 600mg of MEDA Pharmaceuticals Inc., USA among adult epilepsy (partial seizures with or without generalization) subjects already established on a stable adjunctive therapy.
annett Company Inc0 个研究点目标入组 41 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 41
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •A patient fulfilling all the following criteria will be included in the present study:
- •1)Patients willing to provide written informed consent for participation in the study;
- •2)Having ability to comprehend the nature and purpose of the study;
- •3) Willing to be available for the entire study period and to comply with protocol requirements.
- •4)Disease population and treatment condition â??
- •Subjects with documented clinical diagnosis of refractory partial seizures with or without generalization.Subjects with partial seizures with or without generalization not controlled with any of standard antiepileptic regimen of Sodium Valproate (or Valproic acid), Levetiracetam, Gabapentin or Pregabalin at therapeutic levels;
- •5)BMI in the range of 18.5 to 29.99 kg/m2 both inclusive.
- •6)Non-smoker or ex-smoker or mild / moderate smokers and willing to abstain from chewing or smoking any tobacco containing product at least 72.00 hrs prior to first dosing (onset of up-titration) of the study and throughout study.
- •7)Willing to abstain from alcohol or alcoholic products within 24.00 hrs prior to first dosing (onset of up-titration) of the study and throughout the study.
- •8)Willing to abstain from, xanthine or its derivative containing food or beverages (e.g. chocolates, tea, coffee or cola drinks) within 72.00 hrs prior to first prior to first sample collection in each study period and throughout the sampling points.
- •9)Willing to abstain from grapefruit or its juice within 72.00 hrs prior to first prior to first sample collection in each study period and throughout the sampling points.
- •10)Clinically non-significant serum electrolytes (sodium, potassium and chloride).
- •11)With normal or clinically non-significant laboratory values as determined by hematological, biochemistry tests, urine analysis.
- •12) With a normal or clinically non-significant 12-lead ECG.
- •13)In case of female subjects:
- •Negative urine pregnancy test during screening and, negative serum β-HCG test at baseline visits and at check-in for housing during each study period.
- •Patients with child bearing potential or those within their first two years of onset of menopausal syndrome must either abstain from sexual intercourse, or must be using acceptable methods of birth control during the study (Acceptable birth control methods include barrier methods such as diaphragm/condom with spermicide or who are surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy has been performed), but must not use hormonal contraceptive (either oral/implants)).
排除标准
- •A patient fulfilling any one of the following criteria will be excluded from the study:
- •1)Institutionalized patients.
- •2) A history of allergic or hypersensitive reactions Felbamate or other carbamates or to any of the excipients of formulation which in the opinion of an investigator, would compromise the safety of the subject or the study.
- •3)History of aplastic anemia or significant hematological disorder (drug induced or idiopathic).
- •4)History of liver failure or significant liver disease.
- •5)History of suicidal thinking, imminent risk of suicide, or a danger to self or others as judged by the investigator.
- •6)History of psychiatric illness or depression.
- •7)Concurrent use of other drugs known to suppress bone marrow function.
- •8)Liver enzyme (SGPT and SGOT) levels >2 times the upper limit of normal values at baseline and during the entire study.
- •9)Clinically significant drop in the red blood cells, white blood cells and platelet counts at baseline and during the entire study.
- •10)Subjects with any of the following seizure criteria during the study from the date of study onset (baseline):
- •2-fold increase in the highest, 2-day pre-study seizure frequency.
- •Single, generalized, tonic-clonic seizure if none occurred during pre-treatment screening, and/or
- •Significant prolongation of generalized, tonic-clonic seizures.
- •11)A medical or surgical condition that might interfere with the absorption, metabolism, or excretion of Felbamate during the study.
- •12)Significant history or current evidence of malignancy or chronic infectious, cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic (endocrine), hematological, gastrointestinal, immunological or psychiatric diseases, or organ dysfunction, which in the opinion of an investigator, would compromise the safety of the subject or the study;
- •13)Expected changes in the concomitant medications during the study periods.
- •14)Expected incompliance with outpatient medications.
- •15)A history of alcohol or drug dependence by DSM-V-TR criteria during the 6-month period immediately prior to study entry;
- •16)Positive alcohol breath or urine drug of abuse tests during randomization, or at check-in for housing during each study period.
- •17)Positive test for Human Immunodeficiency virus (HIV) type I/II antibodies or Hepatitis B surface antigen (HBsAg) or Hepatitis C virus (HCV) antibodies.
- •18)In case of female subjects:
- •Planning to become pregnant
- •Lactating or nursing subjects
- •19)Participated in any clinical investigation requiring repeated blood sampling, blood donation, or have blood loss of >500 mL in past 8 weeks or participated in any clinical study within the past 3 months prior to first dosing (onset of up-titration) of the study.
- •20)Any major illness or hospitalization within 90 days prior to first dosing (onset of up-titration) of the study.
- •21)History of difficulty in accessibility of veins in arms.
研究者
相似试验
尚未招募
不适用
Steady-state Bioequivalence Study of Clozapine Tablets USP 100mg among Subjects with Schizophrenia in Fasting ConditioCTRI/2016/06/007015Micro Labs Limited India12
招募中
Unknown
Pharmacokinetic Study of Pazopanib in Advanced Renal Cell Carcinoma patientsCTRI/2023/09/057633MSN Laboratories Private Limited
招募中
不适用
Pharmacokinetic Study of Pazopanib in Advanced Renal Cell Carcinoma patientsCTRI/2022/04/042340MSN Laboratories Private Limited
招募中
不适用
Study of Sunitinib malate Capsules 50mg among cancer patients under treatment with stable dose of Sunitinib malate capsules conducted at multiple centers in India where patients will be treated with Sutent 50mg (as Reference) and Sunitinib 50mg by MSN companyCTRI/2019/07/020203MSN Laboratories Private Limited
尚未招募
不适用
Bioequivalence study of Imatinib Mesylate Tablets 400mg in patients with chronic myeloid leukemia or gastrointestinal stromal tumorsCTRI/2018/06/014381Hetero Labs Limited